Skip to main content

Advertisement

SpringerLink
Log in

EMPACT syndrome: limited evidence despite a high-risk cohort

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Serious dermatologic adverse events such as erythema multiforme (EM) and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) have been reported in patients receiving antiepileptic drugs (AEDs) and cranial radiotherapy (RT). Given the frequency of AED-associated rashes and the infrequency of serious dermatologic adverse events after cranial RT, we sought to further assess the prevalence of cutaneous eruptions in patients receiving an AED before and after cranial RT. We reviewed medical records of patients taking AEDs while undergoing RT for a high-grade glioma and recorded demographic, disease, and treatment parameters, as well as the development of rashes. Rashes were found in 19 % of patients taking AEDs. Phenytoin was most commonly implicated (93 %) in rash formation compared with other AEDs (P < 0.0001), both before and during RT. Most rashes (76 %) occurred before starting RT (P < 0.0001). However, of those during RT, most were associated with phenytoin compared with other AEDs (P = 0.002). One case of SJS was noted in a patient receiving phenytoin prior to RT. While rashes were slightly less prevalent in patients receiving temozolomide compared with those not receiving temozolomide (3.4 vs 4.8 %), this difference was not statistically significant (P = 0.65). Rashes are relatively common in patients receiving AEDs, with the highest incidence associated with phenytoin. However, the risk of serious dermatologic events is low. There did not appear to be an association between the receipt of cranial radiotherapy and the development of AED-associated rash with phenytoin or other AEDs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Weller M, Stupp R, Wick W (2012) Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol 13:e375–e382

    Article  PubMed  Google Scholar 

  2. Patel TR, Knisely JP, Chiang VL (2012) Management of brain metastases: surgery, radiation, or both? Hematol Oncol Clin North Am 26:933–947

    Article  PubMed  Google Scholar 

  3. Roujeau JC (1994) The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 102:28–30

    Article  Google Scholar 

  4. Fitzgerald TJ, Jodoin MB, Tillman G, Aronowitz J, Pieters R, Balducci S, Meyer J, Cicchetti MG, Kadish S, McCauley S, Sawicka J, Urie M, Lo YC, Mayo C, Ulin K, Ding L, Britton M, Huang J, Arous E (2008) Radiation therapy toxicity to the skin. Dermatol Clin 26:161–172

    Article  CAS  PubMed  Google Scholar 

  5. Delattre JY, Safai B, Posner JB (1988) Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology 38:194–198

    Article  CAS  PubMed  Google Scholar 

  6. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R (1999) Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study group of the international case control study on severe cutaneous adverse reactions. Lancet 353:2190–2194

    Article  CAS  PubMed  Google Scholar 

  7. Ahmed I, Reichenberg J, Lucas A, Shehan JM (2004) Erythema multiforme associated with phenytoin and cranial radiation therapy: a report of three patients and review of the literature. Int J Dermatol 43:67–73

    PubMed  Google Scholar 

  8. Micali G, Linthicum K, Han N, West DP (1999) Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies. Pharmacotherapy 19:223–227

    Article  CAS  PubMed  Google Scholar 

  9. Aydogan K, Vatansever S, Adim SB, Saricaoglu H (2010) Empact syndrome: a case report and review of the literature. Int J Dermatol 49:945–949

    PubMed  Google Scholar 

  10. Fabbrocini G, Panariello L, Pensabene M, Lauria R, Matano E, Martellotta D, Bianca D, De Placido S, Ayala F (2013) EMPACT syndrome associated with phenobarbital. Dermatitis 24:37–39

    Article  CAS  PubMed  Google Scholar 

  11. Vern-Gross TZ, Kowal-Vern A (2012) Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: a literature review. Am J Clin Oncol

  12. Goyal S, Biswas A, Puri T, Mohanti BK (2010) Stevens-Johnson syndrome following concurrent phenytoin and holocranial radiotherapy. Acta Oncol 49:259–260

    Article  PubMed  Google Scholar 

  13. Oner Dincbas F, Yoruk S, Demirkesen C, Uzel O, Koca S (2004) Toxic epidermal necrolysis after cranial radiotherapy and phenytoin treatment. Onkologie 27:389–392

    Article  CAS  PubMed  Google Scholar 

  14. Eralp Y, Aydiner A, Tas F, Saip P, Topuz E (2001) Stevens-Johnson syndrome in a patient receiving anticonvulsant therapy during cranial irradiation. Am J Clin Oncol 24:347–350

    Article  CAS  PubMed  Google Scholar 

  15. Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, Chin SW, Chiou CC, Chu SC, Ho HC, Yang CH, Lu CF, Wu JY, Liao YD, Chen YT (2008) Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14:1343–1350

    Article  CAS  PubMed  Google Scholar 

  16. Hu FY, Wu XT, An DM, Yan B, Stefan H, Zhou D (2011) Phenytoin-induced Stevens-Johnson syndrome with negative HLA-B*1502 allele in mainland China: two cases. Seizure 20:431–432

    Article  PubMed  Google Scholar 

  17. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MH (2007) Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48:1015–1018

    Article  CAS  PubMed  Google Scholar 

  18. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ (1995) Activation of drug-specific CD4+ and CD8 + T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 155:462–472

    CAS  PubMed  Google Scholar 

  19. Basaran N, Hincal F, Kansu E, Ciger A (1994) Humoral and cellular immune parameters in untreated and phenytoin-or carbamazepine-treated epileptic patients. Int J Immunopharmacol 16:1071–1077

    Article  CAS  PubMed  Google Scholar 

  20. Tubiana M (1981) Does post-operative radiotherapy faclitate metastatic disseminations? In: Dubois JB, Serrouo B, Roseneld C (eds)  Immunopharmacologic basis of radiation therapy. Raven Press, New York, pp 399–414

  21. Gaber MW, Sabek OM, Fukatsu K, Wilcox HG, Kiani MF, Merchant TE (2003) Differences in ICAM-1 and TNF-alpha expression between large single fraction and fractionated irradiation in mouse brain. Int J Radiat Biol 79:359–366

  22. Mockenhaupt M (2011) The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 7:803–815

  23. Teraki Y, Shibuya M, Izaki S (2009) Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations. Clin Exp Dermatol 35:723–728

  24. Musio D, Parisi E, Dionisi F (2009) Irradiated fields spared Stevens-Johnson syndrome in a patient undergoing radiotherapy for bone metastases. Jpn J Radiol 27:103–106

  25. Sanz A, Del Valle M (2005) A man whose scapula was spared a drug-associated rash. Can Med Assoc J 15:745

  26. Mitra SS, Simcock R (2006) Erlotinib induced skin rash spares skin in previous radiotherapy field. J Clin Oncol 24:e28–e29

    Article  PubMed  Google Scholar 

  27. ACR Committee on Drugs and Contrast Media (2013) ACR Manual on Contrast Media, Version 9. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2013_Contrast_Media.pdf

Download references

Acknowledgments

MC was supported by the Medical Student Summer Fellowship Research Program by the Brain Tumor Center at Memorial Sloan-Kettering Cancer Center.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, 10065, USA

    Andrew J. Bishop, Maria Chang & Christopher A. Barker

  2. Department of Medicine, Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, 10065, USA

    Mario E. Lacouture

Authors
  1. Andrew J. Bishop
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mario E. Lacouture
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christopher A. Barker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher A. Barker.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 118 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bishop, A.J., Chang, M., Lacouture, M.E. et al. EMPACT syndrome: limited evidence despite a high-risk cohort. J Neurooncol 119, 129–134 (2014). https://doi.org/10.1007/s11060-014-1457-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1457-7

Keywords

Search

Navigation